Antoine Depaulis Director of Research, Group Leader

Course and current status


1981 Master in Neuroscience (DEA), Université Louis Pasteur, Strasbourg

1983 PhD in Neuroscience (doctorat de 3ème cycle), Université Louis Pasteur, Strasbourg

1986 Master in Pharmacology and Pharmacochemistry (DEA), Université Louis Pasteur, Strasbourg

1990 PhD in Pharmacology (doctorat d’Université), Université Louis Pasteur, Strasbourg

1994 Habilitation à Diriger des Recherches, Université Louis Pasteur, Strasbourg


Research positions and responsabilities

1986  Chargé de Recherches INSERM de 2ème classe (CR2), Strasbourg

1990   Chargé de Recherches INSERM de 1ère classe (CR1), Strasbourg

1999  Directeur de Recherches INSERM de 2ème classe (DR2), Strasbourg

2003   Directeur de Recherches INSERM (DR2) and Director of « Jeune Equipe 2413 », Université Joseph Fourier, Grenoble

2005   Directeur de Recherches INSERM (DR2) and Team leader at U704 Inserm-UJF, Grenoble

2007  Directeur de Recherches INSERM (DR2) and Director of Team #9 « Dynamic of epileptic synchronous networks » at Grenoble-Institute of Neuroscience, U836 Inserm-Université, Grenoble Alpes

 2010-2013  Deputy Director of Grenoble-Institute of Neuroscience

2014  Directeur de Recherches INSERM (DR1) and Director of Team  « Synchronization and Modulation of Neuronal Networks in Epilepsy » at Grenoble-Institute of Neuroscience, U1216 Inserm-University Grenoble Alpes

Scientific summary

During the last 30 years, I have developed an expertise in the pathophysiology of epilepsy and the development of animal models. When in Strasbourg, I actively participated in the validation of the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) and I am now in charge of the maintenance of this strain. Using this model and others, I characterized the control of epileptic seizures by the basal ganglia and this concept has led to several clinical validations and applications for neurostimulation. Since my move to Grenoble in 2003, I created a translation research group composed of clinicians and biologists (n=12-20) which is dedicated to the understanding of epilepsy and the development of new therapies. In particular, we have developed a new model of mesiotemporal lobe epilepsy in the mouse and have characterized its electroclinical, histological and pharmacological similarities with the human pathology. I have obtained fundings and have coordinated several successful and productive research projects involving colleagues with different expertises.

Image d’exemple